3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Thrombocytopenia
9
Leukemia, Myeloid, Acute
8
Leukemia
6
Leukemia, Myelomonocytic, Chronic
4
Myelodysplastic Syndromes
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Jacobs syndrome
2
Hematologic Neoplasms
2
Congenital Abnormalities
2
Solid Tumor, Childhood
1
Sarcoma
1
Recurrence
1
Purpura, Thrombocytopenic, Idiopathic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Connective and Soft Tissue
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
pembrolizumab
4
Trastuzumab
4
Oxaliplatin
4
Fluorouracil
4
Cyclophosphamide
4
Carboplatin
4
Radiotherapy
3
Paclitaxel
3
Endoscopy
3
Docetaxel
3
Cytarabine
3
Chemoradiotherapy
3
Capecitabine
3
toripalimab
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Observation
2
Neoadjuvant Therapy
2
Metformin
2
Magnetic Resonance Imaging
2
Leucovorin
2
Irinotecan
2
Immunotherapy
2
Immune Checkpoint Inhibitors
2
Epirubicin
2
Drug Therapy
2
Doxorubicin
2
Cisplatin
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pathologic Complete Response
×
eltrombopag
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts